Skip to main content

30-09-2019 | Renal cell carcinoma | Video | Article

Researcher comment: TITAN-RCC findings show efficacy of tailored immunotherapy approach

Marc-Oliver Grimm talks through the results of the tailored nivolumab plus boost ipilimumab approach used in the TITAN-RCC study (3:38).

Receive weekly updates on the oncology news that matters

Read the transcript

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Back to the WCLC 2019 conference hub

Related topics